Successful Conversion of Collateral Ventilation Status Using the AeriSeal® System Enables Bronchoscopic Lung Volume Reduction with One-Way Valves: CONVERT Trial
Respiration · 16.11.2026
DOI: 10.1159/res/aepag027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, online erschienen am 16.11.2026. Verfasst von Michela Bezzi und 28 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rationale
Bronchoscopic lung volume reduction (BLVR) with endobronchial valves is effective primarily in patients without collateral ventilation (CV–), leaving limited options for patients with collateral ventilation (CV+) in the target lobe. AeriSeal, delivered bronchoscopically, may occlude collateral channels and enable subsequent valve treatment.
Objectives
To prospectively evaluate whether AeriSeal can convert target lobes from CV+ to CV– status in severe emphysema, enabling subsequent treatment with Zephyr valves.
Methods
Patients with severe COPD/emphysema, fissure completeness ≥80% on quantitative CT, and Chartis-confirmed collateral ventilation-positive (CV+) status were enrolled. Eligible subjects had fissure defects involving no more than three segmental airways. AeriSeal foam (≤40 mL) was administered bronchoscopically in one or two sessions, and CV status was reassessed after 6 weeks. Subjects converting to CV– status underwent Zephyr valve placement. Primary endpoints were successful CV conversion and target lobe volume reduction (TLVR ≥350 mL) 45 days after valve implantation. Measurements and Main Results: Among 101 subjects, 75/99 evaluable patients achieved CV conversion (75.8%; 95% exact CI, 66.1–83.8%). Following valve treatment, TLVR ≥350 mL was achieved in 64/72 evaluable subjects (88.9%; 95% exact CI, 79.3–95.1%), with mean TLVR of 1062.5 ± 676.2 mL at 45 days, sustained through 12 months. At 6 months, post-bronchodilator FEV₁ improved by 0.08 L, residual volume decreased by 0.49L, SGRQ improved by 6.4 points, and mMRC by 0.8 points. Common serious adverse events included post-acute inflammatory response (PAIR; 16.7%), pneumothorax (19.2% within 45 days post-valves), COPD exacerbation, and pneumonia. Three deaths occurred, including one probably valve-related.
Conclusions
AeriSeal effectively converts collateral ventilation status in most treated patients, enabling successful valve therapy with durable lobar volume reduction and acceptable safety.
Autor:innen und Institutionen
ORCID-Profile: Pallav L Shah, Ralf-Harto Hübner, Dirk-Jan Slebos, Karin Klooster, Jacopo Saccomanno
Zitieren
APA
Bezzi, M., Ing, A. J., Egenod, T., Guibert, N., Shah, P. L., Kemp, S. V., Herth, F., Bashirzadeh, F., Hübner, R. H., Slebos, D. J., Kirk, A. J., Steinack, C., Franzen, D., Kornaszewska, M., Tonkin, J., Klooster, K., Levi, G., Piluso, V., Williamson, J. P., …, & Darwiche, K. (2026). Successful Conversion of Collateral Ventilation Status Using the AeriSeal® System Enables Bronchoscopic Lung Volume Reduction with One-Way Valves: CONVERT Trial. Respiration. https://doi.org/10.1159/res/aepag027
Vancouver
Bezzi M, Ing AJ, Egenod T, Guibert N, Shah PL, Kemp SV, et al. Successful Conversion of Collateral Ventilation Status Using the AeriSeal® System Enables Bronchoscopic Lung Volume Reduction with One-Way Valves: CONVERT Trial. Respiration. 2026. doi:10.1159/res/aepag027
BibTeX
@article{Bezzi2026,
author = {Bezzi, Michela and Ing, Alvin J and Egenod, Thomas and Guibert, Nicolas and Shah, Pallav L and Kemp, Samuel V and Herth, Felix and Bashirzadeh, Farzad and Hübner, Ralf-Harto and Slebos, Dirk-Jan and Kirk, Alan Jb and Steinack, Carolin and Franzen, Daniel and Kornaszewska, Malgorzata and Tonkin, James and Klooster, Karin and Levi, Guido and Piluso, Venere and Williamson, Jonathan P and Saghaie, Tajalli and Brock, Judith Maria and Kontogianni, Konstantina and Bilancia, Rocco and Saccomanno, Jacopo and Radhakrishnan, Sri and Armstrong, Brian R and Shargill, Narinder S and Karpf-Wissel, Ruediger and Darwiche, Kaid},
title = {Successful Conversion of Collateral Ventilation Status Using the AeriSeal® System Enables Bronchoscopic Lung Volume Reduction with One-Way Valves: CONVERT Trial},
journal = {Respiration},
year = {2026},
doi = {10.1159/res/aepag027}
}
EUVIMED